Multicenter, first-line metastatic open-label prospective phase II trial evaluating the combination of Palbociclib (CDK 4/6 Inhibitor) and hormone therapy (Letrozole or Anastrozole) in women with luminal, HER2 negative advanced breast cancer: Evaluation of the prediction of individual treatment efficacy using infrared laser spectroscopy analysis on liquid biopsies (Quantum Optics)
Device
Multicenter, first-line metastatic open-label prospective phase II trial evaluating the combination of Palbociclib (CDK 4/6 Inhibitor) and hormone therapy (Letrozole or Anastrozole) in women with luminal, HER2 negative advanced breast cancer: Evaluation of the prediction of individual treatment efficacy using infrared laser spectroscopy analysis on liquid biopsies (Quantum Optics)
Protocol number
ICRG 0201 V 10.0
License Number
King Saud University
Status
Ongoing
Trial site
King Faisal Specialiist Hospital and Research Centre, Riyadh
